AMORFIX ALZHEIMER'S TEST DETECTS AGGREGATED BETA AMYLOID IN HUMAN CSF

TSX: AMF

TORONTO, Jan. 7 /CNW/ - Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced preliminary results indicating that their human Alzheimer's disease (AD) diagnostic assay can detect a signal from aggregated beta amyloid in the spinal fluid (CSF) from AD patients. "These results represent a significant first step towards our goal of developing and commercializing an assay that will accurately identify patients with AD, a disease that currently affects more than 5 million people in North America, a number that is expected to grow dramatically as the population ages" said Dr. Robert Gundel, Amorfix President and Chief Executive Officer.  "While there is still work to do, this represents an important milestone towards the development of a valuable asset for our company.  A new diagnostic tool could enable the early detection and subsequent treatment of AD, while being a major adjunct to clinical research in the field."    

Alzheimer's disease is a chronic neurodegenerative illness characterized in part by memory loss, confusion, disorientation, and mood changes. Currently, the only definitive diagnostic for AD is post-mortem examination of brain tissue to detect neurofibrillary tangles and deposits of aggregated misfolded beta amyloid in plaques in and around neural tissue.  "The benefit of the Amorfix assay is the ability to detect a signal in CSF, which reflects the presence of aggregated beta amyloid in the brain" said Dr. Louise Scrocchi, Associate Director of Research and Development.  This is an important first step in the development of a test to screen and monitor patients undergoing experimental therapies to reduce amyloid load." 

"The availability of an important diagnostic tool such as our A4 assay will facilitate research efforts into disease mechanisms behind AD, as well as enable the development of better treatments" said Dr. Neil Cashman, Amorfix Chief Scientific Officer.

About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is a product development company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including Alzheimer's Disease (AD), cancers, and ALS. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes ("DSEs") on the molecular surface of misfolded proteins. Amorfix's lead programs include therapeutics and companion diagnostics for cancers, antibodies and vaccines to DSEs in ALS and AD diagnostic tests. In addition, Amorfix's proprietary Epitope Protection™ technology enables it to specifically identify very low levels of misfolded proteins in a biological sample. The Company's diagnostic programs include an ultrasensitive method for the detection of aggregated beta-Amyloid in brain tissue, CSF and blood from animal models of AD, months prior to observable amyloid formation, and development of a human screening test for AD. For more information about Amorfix, visit www.amorfix.com.

Forward-Looking Statements
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Amorfix Life Sciences Ltd.

For further information: